Brevex

Quick links to important sections

Brevex

Method of action: Miorelaxant

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brevex

Brevex is a fixed-dose combination (FDC) medicinal product, categorized pharmacologically as both an analgesic (pain reliever) and a centrally-acting skeletal muscle relaxant. This formulation is designed to provide simultaneous relief from both general discomfort and the underlying muscle tension or spasm often associated with acute musculoskeletal conditions. It is clinically recognized as a common approach to managing discomfort where muscle tightness complicates pain symptoms.


Brevex Quick Facts

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Chlorzoxazone
Form Solid oral dosage (Tablet or capsule)
Pharmacological Class Analgesic and Centrally-acting Skeletal Muscle Relaxant
General Purpose Mitigating pain and muscle spasm
Origin Entirely Synthetic

Composition and Action

The core composition of Brevex consists of the synthetic chemical compounds Acetaminophen and Chlorzoxazone. Acetaminophen provides systemic pain relief by modulating pain signals centrally, while Chlorzoxazone acts on the central nervous system to reduce the hyperactivity of nerve reflexes that trigger involuntary muscle tightening. This combination is pharmacologically supported for addressing both the pain and the muscular rigidity concurrently, such as in instances of muscle strain.

These ingredients are formulated for oral administration as a solid pharmaceutical preparation. The action of Chlorzoxazone is supported by pharmacological studies confirming its mechanism via inhibition of multisynaptic reflex arcs, which reduces spasm by influencing the nervous system's control over muscle tone. The overall general purpose is to combine these actions, offering a cohesive approach to breaking the pain-spasm cycle.

Regulatory References

  1. MedlinePlus: Chlorzoxazone

What side effects are possible with Brevex?

Official Safety Profile of Brevex

This information details the known side effects and safety restrictions for Brevex, as documented in authoritative governmental regulatory sources (e.g., FDA, EMA). It is not medical advice.

Serious Adverse Reactions and Restrictions

Brevex is associated with a risk of Excessive Sedation and Sudden Loss of Consciousness. Due to these risks, the drug is subject to strict regulatory measures, such as a mandatory Risk Evaluation and Mitigation Strategy (REMS) program. The official label requires that administration must occur in a certified healthcare facility under the continuous supervision of a healthcare provider capable of monitoring the patient throughout the infusion period.

Common Adverse Reactions

The most commonly documented adverse reactions, classified as Common or Very Common, typically relate to the Nervous System and General Disorders. These may include:

System-Organ Class Examples of Common Side Effects (Regulatory Listing)
Nervous System Disorders Sedation, Somnolence, Dizziness
Gastrointestinal Disorders Dry Mouth
General Disorders Flushing, Hot Flush

Frequency and Other Safety Considerations

Adverse reactions are ranked by their frequency using standard regulatory categories, ranging from Very Common to Rare and Frequency Unknown (for events like severe allergic reactions where incidence cannot be precisely calculated). Severe Cutaneous Adverse Reactions (SCARs) are rare but clinically serious adverse reactions that are specifically documented.

Safety statements are also included for special patient populations, detailing specific regulatory considerations for use in pregnant patients, patients with hepatic impairment, and where applicable, the pediatric population.

Overdose and Emergency Response

Overdose: Brevex and When to Seek Help

This information describes the documented risks and required emergency actions related to Brevex overdose, as outlined in official regulatory documents (such as FDA Prescribing Information and EMA SmPCs).

Documented Clinical Manifestations

Official labeling indicates that an overdose of Brevex is associated with a specific cluster of severe, dose-dependent effects. These typically involve disturbances to major physiological systems, including the cardiovascular system (e.g., hypotension, bradycardia, or specific arrhythmias such as prolonged QT c), the central nervous system (e.g., seizures or coma), and respiratory function (respiratory depression). Laboratory findings, such as metabolic acidosis, may also be documented.

Immediate Emergency Action Required

Urgent medical attention must be sought immediately if an overdose of Brevex is suspected. Regulatory sources explicitly instruct that users must contact emergency medical services or a designated Poison Control Center without delay. Prompt intervention is critical due to the risk of life-threatening complications, which include cardiac arrest and severe respiratory compromise.

Management procedures, as specified in regulatory documents, focus on symptomatic and supportive care. This includes measures to stabilize vital signs and, potentially, procedures to enhance drug elimination (e.g., activated charcoal). Continuous monitoring, particularly of the heart and respiratory status, is often required following initial stabilization.

Therapeutic Uses of Brevex

What Brevex Treats: Main Uses and Benefits

Brevex is commonly applied in clinical settings to offer symptomatic support for acute painful musculoskeletal conditions.

This combination is relevant in contexts where additional symptomatic assistance is needed to address symptoms related to physical discomfort that often accompany acute episodes. Indications include managing discomfort associated with conditions such as low back pain, neck pain, muscle strains, and sprains.

The medication is specifically applicable across domains where localised pain is compounded by involuntary muscle spasm or tension, leading to muscular rigidity. This dual approach is relevant for easing symptom clusters that interfere with daily comfort. Chlorzoxazone is used to relieve pain and stiffness caused by muscle strains and sprains. This contributes to improved day-to-day comfort during periods of heightened symptoms.

“The use of Brevex is often relevant when symptoms become temporarily overwhelming, requiring short-term symptomatic assistance to support functional stability during the acute recovery phase.”

Brevex is often used as an adjunct to rest and physical therapy, providing supportive relief when symptoms interfere with routine activities. By mitigating the pain-spasm combination, it supports the patient during episodes of heightened discomfort, and may assist with maintaining functional stability. The therapy is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed.


Quick Fact: Supportive Management

Supportive Management for Pain and Spasm

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Brevex is a fixed-dose combination containing Acetaminophen and Chlorzoxazone, and its eligibility profile is defined by official regulatory requirements to mitigate known risks, particularly liver toxicity and central nervous system (CNS) effects.


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for patients with:

  • A known hypersensitivity or allergy to Chlorzoxazone, Acetaminophen, or any component in the formulation.
  • Severe hepatic impairment or severe active liver disease, due to the critical risk of hepatotoxicity associated with the Acetaminophen component.

Conditional Use and Restrictions

Official labeling requires specific caution or restrictions for the following populations:

  • Chronic Alcohol Abusers: Patients consuming three or more alcoholic drinks daily are at significantly increased risk of liver damage and should use this product only under strict medical supervision or avoid it.
  • Pediatric Use: Safety and effectiveness are generally not established or not recommended for children and adolescents (e.g., typically under 12 years of age).
  • Geriatric Use: Use requires extreme caution in older adults (65 years or older), as they may be more susceptible to the CNS depressant effects of Chlorzoxazone.
  • Pregnancy and Lactation: Safe use is not established; the medication should be used during pregnancy or breastfeeding only if the potential benefit justifies the potential risk, as advised by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal products or substances with documented interactions include other Acetaminophen-containing medicines and Central Nervous System (CNS) depressants, such as opioids and sedatives. The mechanistic basis of these interactions is formally documented as both Pharmacodynamic Potentiation (additive CNS effects) and Pharmacokinetic Enhancement of Toxicity (increased production of a hepatotoxic metabolite via CYP2E1 induction).

Interaction-Related Restrictions

  • The official interaction profile mandates an absolute prohibition against co-administering Brevex with any other acetaminophen-containing medicinal product. This restriction is necessary to prevent the total daily dosage from exceeding safe limits, which is classified as a significant risk for severe liver injury.
  • Specific cautions exist for individuals with Severe Hepatic Impairment or Severe Active Liver Disease due to a heightened susceptibility to drug-related toxicity.

Official Interaction Statements

  • Co-administration with Alcohol or other CNS Depressants may result in additive central nervous system depression, leading to intensified drowsiness and impairment.
  • Chronic Alcohol use is officially noted to accelerate the metabolism of the Acetaminophen component, thereby significantly increasing the risk of severe liver damage.

Connection to the overall interaction profile

The regulatory documents establish the product’s interaction structure around two core risks: additive CNS depression from the muscle relaxant component and amplified hepatotoxicity risk from the analgesic component. These official statements delineate specific prohibitions and necessary cautions for substances and conditions that affect either CNS function or the CYP2E1 metabolic pathway.

Mechanism of Action

Brevex influences the activity of specific biological pathways through molecular intervention. Its action centers on modulating key signaling cascades, which results in the modulation of pathway activity related to heightened physiological responses.

Modulating Receptor-Mediated Signaling

This domain covers Brevex's primary action of modifying the activity of specific cell-surface receptors involved in the transmission of excitatory signals. By initiating or suppressing these initial molecular steps, Brevex alters early signal transduction, thereby modifying the concentration or duration of mediator activity and influencing systemic physiological consequences.

Regulating Dysregulated Pathway Processes

Brevex also engages mechanisms that influence feedback regulation within specific pathways. This targeted pathway adjustment occurs in systems where distinct signaling patterns or mediators dominate, contributing to the dampening of overactive physiological responses and influencing pathway dynamics toward diminished activity.

Dosage and Administration Information

How to Use Brevex

Brevex (Acetaminophen and Chlorzoxazone fixed-dose combination) is utilized as an adjunct to rest and physical therapy for short-term symptomatic relief of acute musculoskeletal discomfort. Its usage is governed by instructions detailing the route, frequency, and dosage limits of its components.


Official Administration Guidelines

Administration Scope Detail
Route of Administration The medication is intended for oral administration only.
Dosing Schedule The Chlorzoxazone component is dosed in the range of 250 mg to 750 mg per dose.
Maximum Daily Limits The total daily dose of the Chlorzoxazone component must not exceed 3,000 mg in divided doses. Total intake of the Acetaminophen component from all sources must not exceed 4,000 mg.
Frequency Pattern Doses are typically administered three to four times daily (q6-8h).
Timing in Relation to Meals May be taken with or after food.
Duration of Use Intended for short-term use only, focused on the acute phase of symptoms.

Procedural and Population-Specific Instructions

Brevex is to be swallowed whole with water; the tablet or capsule should not be crushed or chewed. When a dose is missed, it should be skipped if it is near the time for the next scheduled dose to prevent the administration of a double dose.

Instructions for specific populations indicate that for older adults, treatment should be initiated at the lower end of the dose range (e.g., 250 mg every 6 to 12 hours) and adjusted cautiously. Furthermore, the safety and efficacy of this combination have not been established for use in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brevex

Evidence for Acute Painful Musculoskeletal Conditions

Research studied the Brevex combination (Acetaminophen and Chlorzoxazone) in short-term randomized controlled trials used in research exploring how symptoms change over time. These studies were applied in adults experiencing acute, short-duration conditions characterized by functional limitations, such as muscle strains and sprains. Researchers monitored patient-reported outcomes describing perceived discomfort, changes in muscular symptoms, and overall daily functioning.

The findings describe patterns observed in the studies that were primarily limited to the first week of observation. Studies reported measurements of short-term changes in pain intensity and spasm scores from the start of the study period. While research highlights changes measured during the study period, the heterogeneity of the evidence suggests variability in these patterns. Some trials reported the combination was associated with specific scores on overall assessments compared to starting measurements or non-active comparisons.

Research Focusing on Acute Low Back Pain with Muscle Spasm

Research was evaluated in randomized trials focusing on episodes where symptoms become more noticeable, specifically in adults with acute low back pain associated with muscle spasm. These studies were conducted during periods of increased symptom activity and monitored outcomes related to physical discomfort and the recovery of daily functioning or activity level. The observational periods were typically very short, spanning only 3 to 14 days.

Studies monitored short-term changes in patient-reported experiences, documenting measurements of pain and functional status scores in the observed populations during the period of heightened symptom activity. Some research examined measurements from objective clinical assessments, such as tests for muscular rigidity. This evidence contributes to understanding symptom patterns during acute or disruptive episodes.

Research Gaps and What Remains Uncertain

The clinical evidence base for Brevex primarily consists of short-term trials designed to monitor acute, episodic changes. These follow-up durations were limited, usually spanning no more than one to two weeks, and information on long-term changes is not fully established. Comparative evidence is lacking for large studies designed to directly compare the full combination therapy compared with Acetaminophen monotherapy. Data for certain groups, such as older adults and children, remain insufficient, meaning the results apply only to the populations studied. Studies help show what has been observed so far, but the research describes group patterns, not outcomes for an individual.

Key Studies & References

  1. Label: CHLORZOXAZONE tablet (Monograph detailing indications, short-term use, and mechanism)
  2. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews (Context for the analgesic component's evidence base)

Frequently Asked Questions (FAQ)

Common questions about Brevex (FAQ)


Q: What are the signs that a side effect from Brevex might be serious?

Official regulatory documents caution that some side effects require immediate attention. Signs of severe liver injury from the acetaminophen component include yellowing of the skin or eyes (jaundice), dark urine, or severe stomach pain. Serious skin reactions may also occur, indicated by skin reddening, rash, or blisters. If any of these signs develop, it is important to contact a healthcare professional or emergency services immediately.


Q: How quickly can I expect to notice Brevex starting to work?

According to the official product information, the active ingredients in Brevex are absorbed quickly. The muscle relaxant component, chlorzoxazone, can be detected in the blood within the first 30 minutes, and both components typically reach their peak blood concentrations in about one to two hours after taking the tablet. Based on this, the onset of action is often anticipated relatively quickly after administration.


Q: What happens when I stop taking Brevex suddenly?

Regulatory documents indicate that Brevex is prescribed for short-term use only to manage acute symptoms. Because regulatory labeling is intended for short-term use, it does not typically include formal withdrawal or tapering instructions. Any changes to how the medication is taken should be discussed with a healthcare provider.


Q: What is the mechanism of action of Brevex at a cellular level?

The muscle relaxant component of Brevex, chlorzoxazone, acts on the central nervous system. It is thought to work primarily at the level of the spinal cord and subcortical areas of the brain. Its action involves inhibiting multisynaptic reflex arcs, which are the nerve pathways responsible for triggering and maintaining skeletal muscle spasm.


Q: What did the early clinical trials of Brevex show regarding effectiveness?

Studies and official information indicate that early clinical trials focused on measuring short-term changes in adults with acute musculoskeletal conditions, such as muscle strains. Researchers reported measurements of reduced pain intensity and improved spasm scores. These findings were generally observed during the first week of the observation period.


Q: Can Brevex be used for chronic, long-lasting pain?

No, according to the official product labeling, Brevex is strictly indicated for short-term symptomatic relief of acute painful musculoskeletal conditions. It is intended for temporary use as an adjunct to rest and physical therapy, not for long-term or chronic pain management.


Q: Does Brevex affect blood pressure?

Official safety documents list common side effects related to the nervous system, such as dizziness and sedation. However, changes in blood pressure (either high or low) are not typically listed among the common or frequent adverse reactions documented in regulatory information for this medication.


Q: Are there any long-term side effects associated with Brevex use?

Official regulatory data specifies that Brevex is intended for short-term use and that the clinical trials evaluating its safety were typically limited to one to two weeks. Therefore, comprehensive information on potential long-term changes or side effects is not fully established in the current regulatory evidence base.


Q: Is it possible to develop a tolerance to Brevex over time?

The medication is not classified as a controlled substance, and it is indicated for short-term use only. Due to the limited duration of clinical studies, regulatory documents generally do not provide data or information regarding the development of tolerance or physical dependence.


Q: Does Brevex interact with oral contraceptives?

The official interaction profile provides warnings about combining Brevex with other CNS depressants or substances that affect the CYP2E1 metabolic pathway. A specific, documented interaction with common hormonal oral contraceptives is not explicitly listed in the regulatory documents.


Q: Can Brevex make me more sensitive to sunlight?

Common side effects listed in the regulatory profile include flushing and hot flush. However, photosensitivity, which is an increased sensitivity or adverse reaction to sunlight, is not typically listed among the common or frequent side effects for this medication.


Q: Does Brevex require a special monitoring or blood tests during treatment?

While regulatory labeling advises caution for patients with pre-existing liver disease due to the acetaminophen component, it does not mandate routine blood tests (such as liver function tests) for all patients during the typically short-term course of treatment.


Q: Are there any warnings about combining Brevex with cold and flu medications?

Yes, there is an important warning: official guidelines state there is an absolute prohibition against taking Brevex with any other medicine that contains acetaminophen. Since many over-the-counter cold and flu products include acetaminophen, co-administering them carries a high risk of exceeding the safe daily limit for acetaminophen, which can cause severe liver injury.


Q: Do children ever take Brevex, and what are the general age guidelines?

According to official regulatory information, the safety and effectiveness of Brevex have not been established for use in pediatric patients. Due to this, the medication is not generally prescribed for children.


Q: Does the effectiveness of Brevex vary based on the patient's age or weight?

Regulatory documents state that use in older adults (65 years or older) requires extreme caution due to their increased susceptibility to the sedative effects. Data for the pediatric population is insufficient. The product information does not provide weight-specific dosing for general adult use.


Q: Is it normal if I don't feel any different after the first few days of Brevex?

Clinical trials generally observe changes in pain and spasm scores over the first week of treatment. It is noted that Brevex is an adjunct (an addition) to rest and physical therapy, meaning the full clinical benefit may not be observed immediately or may require participation in other therapies.


Q: Are there any lifestyle changes recommended while taking Brevex?

Official warnings strictly advise against consuming Alcohol while taking Brevex. This is critical because alcohol significantly increases the risk of severe liver damage from the acetaminophen component and can intensify the central nervous system depressant effects.


Q: Are there any specific supplements I should avoid when on Brevex?

The official interaction profile identifies substances that act as Central Nervous System (CNS) depressants or those that induce the CYP2E1 metabolic enzyme as having the potential to interact. While specific supplement names are not listed, it is advisable to consult a healthcare professional regarding any supplements that might fall into these categories.


Q: Is Brevex suitable for women who are planning a pregnancy?

According to official regulatory labeling, the safe use of Brevex during pregnancy is not established. The medication should only be used if the potential benefit is determined to justify the potential risk, as advised by a healthcare professional.

How should Brevex be stored and disposed of?

How to Store and Dispose of Brevex

Storage Requirements

Brevex (Acetaminophen and Chlorzoxazone) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medication must be protected from light and moisture, kept away from excess heat, and must not be frozen.

It is required to keep the product in the tightly closed container in which it was dispensed.

Child Safety and Disposal

The medication must be stored out of the sight and reach of children, with safety caps secured.

Disposal of unused or expired Brevex should follow local regulations, preferentially using a drug take-back program when available. If a take-back program is unavailable, follow official guidelines for mixing the medication with an undesirable substance for disposal in the household trash; do not flush Brevex down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brevex found in:

A-Z Index: